RNS Number : 5279Y MaxCyte, Inc. 03 January 2024 MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline Lion TCR to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid
RNS Number : 3554Y MaxCyte, Inc. 02 January 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , January 2 , 2024 - MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
RNS Number : 3253Y MaxCyte, Inc. 02 January 2024 MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director ROCKVILLE, MD , January 2, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
RNS Number : 1118Y MaxCyte, Inc. 29 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 29, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4671W MaxCyte, Inc. 12 December 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 MaxCyte Announces CEO
RNS Number : 0411W MaxCyte, Inc. 07 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 7, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4853V MaxCyte, Inc. 04 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 4, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
ROCKVILLE, Maryland - 1 December 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announcesthat pursuant to its block admission facility, since 31 October 2023 it has issued133,442of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.
ROCKVILLE, MD, November 30, 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 27 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, aNon-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
ROCKVILLE, MD, November 17, 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 14 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, aNon-Executive Director of the Company, exercised options over 10,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
